Skip to content

Biobanking of elderly patients with heart failure and osteoporosis

Biobanking of elderly patients with heart failure and osteoporosis

Status
Active, not recruiting
Phases
Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300076372
Enrollment
Unknown
Registered
2023-10-07
Start date
2023-10-10
Completion date
Unknown
Last updated
2023-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure

Interventions

observation group:None

Sponsors

Affiliated Hospital of Shanxi University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Be 60-80 years old (2) Meet the diagnostic criteria of chronic heart failure with osteoporosis. (3) Cardiac function grade II-III (NYHA cardiac function) (4) Do dual-energy Xray bone density test, T=? -2.5 (5) Be able to understand the procedures and methods of this clinical study, voluntarily participate and sign the informed consent form

Exclusion criteria

Exclusion criteria: (1) Those who are in critical condition and may be life-threatening during the process of studying. (2) Those who have not signed the informed consent form (3) Mental disorders who failure to correctly cooperation. (4) Structural heart disease (valvular heart disease, pericardial disease, congenital heart disease), intracardiac tumor, hypertrophic cardiomyopathy, restrictive (infiltrative) heart disease, et al. (5) Patients with secondary osteoporosis caused by various reasons, such as hyperthyroidism, primary hyperparathyroidism, adrenal tumors,et al. (6) Diseases that affect bone densitometry: such as cancer, paget disease, multiple myeloma, rheumatoid arthritis, ankylosing spondylitis. (7) Patients with serious cardio-cerebral and renal diseases other than heart failure in the past 6 months (8) Patients who have taken sex hormones, glucocorticoids and other drugs that affect bone metabolism within 3 months. (9) Patients are taking drugs that affects the observation of studying drug.

Design outcomes

Primary

MeasureTime frame
Cardiac ultrasound;N-terminal pro-B-type natriuretic peptide;

Secondary

MeasureTime frame
Bone mineral density;vitamin D;Osteoprotectin;chest CT;C-reactive protein;

Countries

China

Contacts

Public ContactZhigeng Hu

Affiliated Hospital of Shanxi University of Chinese Medicine

13835172121@126.com+86 138 3517 2121

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026